tepotinib

Active substance tepotinib
Holder Merck nv/sa
Status closed
Indication Treatment of adult patients with advanced non-small cell lung cancer harboring mesenchymal-epithelial transition factor gene METexon14 (METex14) skipping alterations.
Public documents Approbation
  Information for the patient
  Informed consent
Last update 03/02/2023

 

Last updated on 13/02/2024